<DOC>
	<DOC>NCT00627406</DOC>
	<brief_summary>The purpose of this study is to possibly further improve the clinical outcome and explore the incidence of OHSS in patients, who have final oocyte maturation with GnRHa (Buserelin) in GnRH antagonist IVF/ICSI cycles</brief_summary>
	<brief_title>Triggering of Final Oocyte Maturation With GnRHa (Buserelin) in GnRH Antagonist Cycles</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Hyperstimulation Syndrome</mesh_term>
	<mesh_term>Chorionic Gonadotropin</mesh_term>
	<mesh_term>Buserelin</mesh_term>
	<criteria>Patient complying with the conditions for IVF or ICSI treatment Female age over 20 years and under 40 years Normal regular cycle and patients with oligomenorrhea BMI &gt; 18 and &lt; 35 each patient contributes with one cycle only Significant disturbances in the woman (diabetes, epilepsy, liver/renal/heart disease, metabolic disorder) Patients with &gt; 25 follicles on the day of triggering ovulation</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>39 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>GnRH antagonist</keyword>
	<keyword>GnRH agonist</keyword>
	<keyword>hCG</keyword>
	<keyword>OHSS</keyword>
	<keyword>In vitro fertilization</keyword>
	<keyword>ovulation induction</keyword>
	<keyword>Clinical pregnancy rate</keyword>
</DOC>